Trial reportBritish journal of pharmacology2002
Urotensin II evokes potent vasoconstriction in humans in vivo.
Trial report in British journal of pharmacology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 139 citations in OpenAlex.
- Association between human urotensin II and essential hypertension--a 1:1 matched case-control study.PloS one · 2013Trial
- No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans.British journal of clinical pharmacology · 2002Trial
- Urotensin II Receptor Deletion Mitigates Kidney Injury and Renal Lipid Remodeling in Mice Fed a Long-Term High-Fat Diet.FASEB bioAdvances · 2026Article
- Association of resistin (rs3745367) and urotensin II (rs228648 and rs2890565) gene polymorphisms with risk of type 2 diabetes mellitus in Indian population.Molecular biology reports · 2020Article
- The role of neuropeptides in adverse myocardial remodeling and heart failure.Cellular and molecular life sciences : CMLS · 2017Review
- The G Protein-Coupled Receptor UT of the Neuropeptide Urotensin II Displays Structural and Functional Chemokine Features.Frontiers in endocrinology · 2017Review
- Article
- Urotensin-II: More Than a Mediator for Kidney.International journal of nephrology · 2012Article
- Renal impairment, hypertension and plasma urotensin II.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2011Article
- Potential Clinical Implications of the Urotensin II Receptor Antagonists.Frontiers in pharmacology · 2011Article
- The effects of urotensin II and urantide on forearm blood flow and systemic haemodynamics in humans.British journal of clinical pharmacology · 2009Article
- Endothelial progenitor cells & translational research.British journal of clinical pharmacology · 2009Article
- State-dependent calcium mobilization by urotensin-II in cultured human endothelial cells.Peptides · 2008Article
- Urotensin II in cardiovascular regulation.Vascular health and risk management · 2008Review
- Urotensin II acutely increases myocardial length and distensibility: potential implications for diastolic function and ventricular remodeling.Naunyn-Schmiedeberg's archives of pharmacology · 2007Article
- Therapeutic potential of blockade of the urotensin II system in systemic hypertension.Current hypertension reports · 2007Review
- The role of urotensin II in cardiovascular and renal physiology and diseases.British journal of pharmacology · 2006Review
- The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems.British journal of pharmacology · 2006Article
- In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,DTrp7,Dab8]urotensin II(4-11) (UFP-803).British journal of pharmacology · 2006Article
- Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375.British journal of pharmacology · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The peptide urotensin II (U II) evokes potent vasoconstriction in non-human primates. In human blood vessels studied in vitro variable effects of U II are reported; vasoconstriction, vasodilatation or no response. It is therefore of importance to determine the vascular effect of U II in humans in vivo. U II (0.1 - 300 pmol min(-1)) was infused into the brachial artery of nine healthy volunteers. Changes in forearm blood flow (FBF) were determined by venous occlusion plethysmography. U II induced dose-dependent reduction in FBF. A threshold response was obtained by 1 pmol min(-1), and the highest dose of U II (300 pmol min(-1)) reduced FBF by 31+/-4% (P<0.01). FBF returned to baseline values within 30 min. This study demonstrates that U II produces potent vasoconstriction in humans in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.